Showing results (11-20 of 53) with videos related to
Sort By:
Pageof 6
Oncoimmunology|May 17, 2017
The mutational status of p53 can influence its recognition by human T-cellsKaterina Shamalov, Shlomo N Levy, Miryam Horovitz-Fried, et al.Journal for Immunotherapy of Cancer|May 24, 2019
Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptidesHanan Besser, Sharon Yunger, Efrat Merhavi-Shoham, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 13, 2013
Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activityChen Ankri, Katerina Shamalov, Miryam Horovitz-Fried, et al.Molecular Carcinogenesis|May 12, 2020
Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cellsSara Meril, Ortal Harush, Yishai Reboh, et al.Cancer Research|September 5, 2006
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stabilityCyrille J Cohen, Yangbing Zhao, Zhili Zheng, et al.Journal for Immunotherapy of Cancer|September 11, 2019
A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor functionShiran Hoogi, Vasyl Eisenberg, Shimrit Mayer, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 30, 2010
Selected murine residues endow human TCR with enhanced tumor recognitionGil Bialer, Miryam Horovitz-Fried, Shlomo Ya'acobi, et al.Experientia Supplementum (2012)|February 15, 2022
Adoptive T-cell Immunotherapy: Perfecting Self-DefensesRaphaëlle Toledano Zur, Galit Adler, Katerina Shamalov, et al.ACS Nano|October 14, 2017
Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer ImmunotherapyRinat Meir, Katerina Shamalov, Tamar Sadan, et al.Oncotarget|November 29, 2014
An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificitiesYair Tal, Shlomo Yaakobi, Miryam Horovitz-Fried, et al.Pageof 6